Wednesday, 15 July 2020

Global Venous Blood Collection Devices Market 2019 Analysis By Manufacturers, Latest Trends, Competitive Landscape And Strategies

Market Scenario
The Global Venous Blood Collection Devices Market is expected to expand at a CAGR of 9.3% over the forecast period of 2019-2023, reveals Market Research Future (MRFR) in a detailed study.
Venous blood collection devices are vessels used for collection, sampling, and testing blood samples. These devices are easy to handle, provide mechanical protection as well as protection from contamination and radiation. Moreover, these blood collection devices offer the exact filling volume.
The global venous blood collection devices market trends are driven by the increasing diagnostics and screening for numerous diseases, increasing health awareness leading to growing demand for blood collection devices for sampling, and with the growing preference for disposable products. Product development can be an attractive strategy for expanding the global venous blood collection devices market.
However, restraints that are likely to hinder the growth of the venous blood collection devices market include risks associated with contamination, pressure on prices, and low-quality products from unknown manufacturers. 
The global burden of chronic diseases is increasing at an alarming rate which induces high demand for screening services and consequently boosts the growth of the global venous blood collection devices market. This further complemented by growing disposable income and high health awareness among consumers. To meet the massive demands, medical device manufacturers are endeavoring towards product improvement which jhas resulted in teh devleopment of advanced venous blood collection devices that can be used for safer blood collection. Furthermore expansdion in product oportfolio by key medical device manufacturers have resulted in teh consolidation of teh global venous blood collection devices market. On the other hand, the growth of the market might be undermined by risks related to contamination, pricing pressure, and substandard product from local manufacturers.
Key Players
Some of the key players in the global venous blood collection devices market are Becton, Dickinson and Company (U.S), Bio-Rad Laboratories, Inc. (U.S), NIPRO Medical Corporation (Japan), Qiagen NV (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Greiner Bio One International GmbH (Greiner Group) (Austria), Terumo Medical Corporation (Japan), Sekisui Chemical Co., Ltd. (Japan), Sarstedt AG & Co (U.S.), F.L. Medical (Italy), Narang Medical (India), Soya Green Tec Co., Ltd. (South Korea), Biosigma (U.S.), Vital Diagnostice (ELITech Group) (U.S.), Improve Medical Technology Co. Ltd. (U.S.), Hongyu Medical (China), SanLI (Myanmar.), KHB (U.S.), Zhejiang Gongdong Medical Technology Co., Ltd. (China), CDRICH (China), Radiometer Medical ApS (Danaher Corporation/ Danrad ApS) (Denmark), Medtronic Plc (U.S.), Fisher Scientific (Thermo Fisher Scientific Inc.) (U.S.), Kabe Labortechnik GmbH (Germany), Allegro Medical Supplies Inc. (Scrip Products Corporation) (U.S.), and others.
Segmentation
The global venous blood collection devices market has been segmented on the basis of type, material, application, and end-user.
On the basis of material, the global venous blood collection devices market is segmented into plastic, glass, stainless steel, ceramic, and others.
On the basis of type, the market is segmented into blood collection tubes, needles, vacuum blood collection system, microfluidic system, micro-container tubes, micro-hematocrit tubes, warming devices, and others. Other devices include venous cannula and blood bags. The blood collection tube is further sub-segmented into plasma separation tube, heparin tube, serum separating tube, EDTA tube, and others.
On the basis of application, the venous blood collection market is segmented into vein blood gas sampling and intraoperative blood salvage. Vein blood gas sampling is further sub-segmented into the diagnosis of disease and acid-base status monitoring.
On the basis of end-user, the global venous blood collection devices market is segmented into hospitals and clinics, the point of care, blood donation centers, diagnostic centers, and others.
Regional Analysis                     
The global venous blood collection devices market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure. Gulf nations such as the U.A.E. and Saudi Arabia are projected to drive the Middle Eastern and African market. The government has undertaken various awareness programs for safe blood transfusion procedures which are further improving the health conditions in underdeveloped regions of Africa.
The Americas region accounted for the largest market share of the global venous blood collection devices market owing to the fastest uptake of new surgical techniques and instruments in the North American region, thus driving the venous blood collection devices market. Moreover, the extensive use of screening techniques and high expenditure on health care in the U.S. is driving the market growth. The greater awareness in developed regions along with the good reimbursement scenario drive the Americas venous blood collection devices market.
The European region accounted for the second largest market owing to high income and healthcare penetration. The Asia Pacific region is expected to increase during the forecast period owing to the growing healthcare sector in leading regions such as China and India. The major driving factors of the venous blood collection devices market are the increasing geriatric population, growth in demand for safe blood assortment technologies, increase in demand for improved blood sampling techniques, and increase in preference towards disposable products for the laboratory.
Posted by at No comments:

The Epilepsy Diagnosis & Treatment Market World Leading Key Players Revenue, Share, Analysis And Estimation Till 2023

Synopsis of the Global Epilepsy Diagnosis & Treatment Market
Increasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market trends. However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period. The global epilepsy diagnosis and treatment market is estimated to grow at an approximate CAGR of 6.3% during the forecast period.
Segmentation
The global epilepsy diagnosis and treatment market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into idiopathic, cryptogenic, symptomatic, and others. On the basis of diagnosis, the market is segmented into neurological exam, blood test, imaging, and others. The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others. On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others. The medication segment is sub-segmented into acetazolamide, carbamazepine, clobazam, and others. The surgery segment is sub-segmented into hemispherectomy, corpus callosotomy, resection surgery, and others. The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others. On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.
Regional Analysis
The Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region. Moreover, increasing number of head trauma cases boosts the American market. Europe holds the second largest market share owing to the availability of funds for research, presence of a well-developed healthcare sector, and government support. Followed by Europe, the Asia Pacific region is projected to be the fastest growing region for the global epilepsy diagnosis and treatment market. Presence of developing healthcare sector, along with emerging economies of the Asia Pacific region boosts the market growth. The Middle East & Africa has the least share in the global epilepsy diagnosis and treatment market, owing to the low per capita healthcare expenditures, lack of awareness for the disease, and stringent government policies, especially in the African region. On the other hand, the Middle East region within the Middle East & Africa is estimated to be fastest growing region due to growing healthcare expenditures and presence of the developed economies, such as Kuwait, Qatar, Dubai, and others.
Key Players
The key players for the global epilepsy diagnosis and treatment market are Pfizer, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), UCB Pharma Ltd. (U.K), Abbott (U.S.), GlaxoSmithKline plc (U.K), Novartis International AG (Switzerland), Sanofi S.A. (France), Shire (Republic of Ireland), Medtronic (U.S.), NeuroWave Systems Inc. (U.S.), Natus Medical Incorporated. (U.S.), Siemens Ltd. (Germany), and others.
Posted by at No comments:

Ebstein’s Anomaly Market Strategies And Competitive Analysis, Forecast Till 2023

Market Scenario:
Ebstein's anomaly is a rare congenital disease that occurs due to improper development of the tricuspid valve in the first eight weeks of fetal growth. This disorder occurs when the tricuspid valve that divides the two chambers of the right side of the heart does not form correctly.
The global Ebstein’s Anomaly market is driven by the increasing number of congenital heart diseases and growing population; growing market players has increased the scope of Ebstein’s Anomaly market. Technological advancements, owing to which new and advanced products are being launched in the market, is another factor propelling the growth of this market.
Ebstein's anomaly may be due to many factors, including genetics and the environment. Children born in a family with a history of heart defects may be more likely to have Ebstein's anomaly. The mother's exposure to certain medications, such as lithium, can lead to Ebstein's anomaly in the child.
However, varied stringency of regulatory procedures across the globe and the presence of complex regulatory procedures may hinder the growth of this market.
The global Ebstein’s Anomaly market share is expected to grow at a CAGR of 9.0% during the forecast period.
Key Players                                                                                                         
Some of the key players in fungal eye infection market are Ebstein’s Anomaly market are Abbott Vascular, Boston Scientific Corporation, Cordis Corporation, Edwards Lifesciences, Ge Healthcare, Gore Medical, Medtronic, Inc., Numed, Inc., Siemens Healthcare, St. Jude Medical, and Toshiba Corporation among others.
Segmentation                                                                                                                                            
The global Ebstein’s Anomaly market is segmented on the basis of treatment, diagnosis and end users.
On the basis of diagnosis Ebstein’s Anomaly market is segmented into echocardiogram, electrocardiogram (ECG) chest x-ray, cardiac MRI, Holter monitor, pulse oximetry, exercise stress test, electrophysiology study, and cardiac catheterization.
On the basis of the treatment, the market is segmented medications and surgical treatment. Surgical Treatment is further segmented into tricuspid valve repair, tricuspid valve replacement, closure of the atrial septal defect, and maze procedure.
On the basis of end users, the market is segmented into hospitals & surgical centers, and specialty clinics.
Regional Analysis
North America Ebstein’s Anomaly market is rapidly growing in the American region. On a regional basis, the Americas is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of congenital disorders and growing  population has increased the scope for the Ebstein’s Anomaly market in North America. According to CDC (Centre for Disease Control), it was estimated that about 1 million U.S. children and about 1.4 million U.S. adults were living with CHDs.  Additionally, CHDs affect nearly 1% of―or about 40,000―births per year in the United States.
Europe is the second largest market and holds a healthy share in the global Ebstein’s Anomaly market. The European market is expected to grow steadily during the forecast period owing to the skilled professionals and availability of advanced and accessible treatment facilities. Additionally, wide research and development activities for the treatment of rare disease and increasing government funding boost the market growth.  
Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to the increasing population. Rising awareness about the health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drives the market.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers.
Posted by at No comments:

Tuesday, 14 July 2020

Cough Syrup Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2026

Market Scenario:
The Global Cough Syrup Market expects to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Cough syrups are the medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key factors contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with an active pharmaceutical sector, are boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the Cough Syrupmarket size.
Market Dynamics
Rising air pollution is acting as a driver for the growth of the market. Air pollution is a major environment-related health threat that stands as a risk factor for both acute and chronic respiratory diseases. According to a report by the Forum of International Respiratory Societies (FIRS), tobacco smoke, indoor air pollution from burning fuels, and air pollution from traffic and industrial sources are highlighted as the primary contributing factors for most respiratory conditions. World Health Organization (WHO) estimated that 4.3 million deaths per year could be attributed to indoor air pollution. Most diseases and deaths that can be attributed to prolonged exposure to poor indoor air quality occurs primarily in women and children, especially in low-income families. Exposure to indoor smoke used for heating and cooking leads to COPD, lung cancer, and, in children, it causes pneumonia and asthma. This large population affected with respiratory disorders due to air pollution is driving the market for cough syrup market as it is a crucial medicine used for the treatment of such diseases.
Segmentation
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, the market has been segmented into cough suppressants and expectorants. And by application, the cough syrup market has been categorized as adults and children.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region to combat these concerns effectively through the use of cough syrups.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Players
The prominent players in the global cough syrup market are Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France).
The players operating in the global cough syrup market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In February 2019, Merck invested USD 70 million to expand its research & development (R&D) facility in Billerica, Massachusetts for the development of innovative clinical pipeline products.
  • In July 2018, Johnson & Johnson acquired Zarbee's Naturals, a drug-free children's cough syrup. This enabled the company to broaden its product portfolio globally.
  • In December 2016, Pfizer, Inc., launched a series of products as a line extension under the Corex brand name. The first launch was on December 2016, and subsequent launches were conducted in 2017. These formulations were duly approved by central and state regulators.Bottom of Form
Key Players
  • DJO Global, Inc. (US)
  • BTL Industries (US)
  • Enraf-NoniUS B.V (Europe)
  • Dynatronics Corporation (US)
  • EMS Physio (UK)
  • ITO Co. Ltd (Japan)
  • Mectronic Medicale (Europe)
  • Performance Health (Subsidiary of Madison Dearborn Partners) (US)
  • Whitehall Manufacturing (US)
  • Zimmer Medizinsysteme GmbH (Germany)
  • Colfax Corporation (US)
  • STORZ MEDICAL (US)Top of Form

Posted by at No comments:

Covid-19 Impact On Clear Aligners Market 2020: Growth Trends, Cost Structure, Driving Factors And Future Prospects 2025

Clear Aligners market is anticipated to expand at a CAGR of 20.80% in the duration of the forecast period. Market Research Future presents Clear Aligners Industry future scope with Information by Product Type (Hard, Medium and Soft), Age (Adult and Teenager), Distribution Channel (Direct Sales and Laboratories) and Regional Analysis, Forecast till 2025
The increasing level of acceptance and demand for clear aligners is amplifying the expansion of the market steadily. The benefits of clear aligners are multiplying the number of individuals who are opting for it. This is primarily due to the improving number of individuals electing for cosmetic dental procedures since the past few years. The clear aligners market is expected to progress at a 20.80% CAGR while earning revenues worth USD 3982.30 Million in the duration of the forecast period. The evolution in terms of technology such as 3D printing, dental CAD software, and thermoforming machines is projected to transform the market favorably in the coming years.
Rapid technological advancement is aiding the evolution of dentistry with the development of advanced dental devices. Rise in prevalence of dental diseases and increase in geriatric population all over the world are inducing high demand for advanced dental devices which is leading to the significant growth of the global clear aligners market. High healthcare expenditure in developed and developing regions and increasing popularity of aesthetic dentistry among young population have created multiple opportunities for the expansion of the global clear aligners market. However, the treatment time required for clear aligners is comparatively higher than other procedures. Hence, the high treatment time, availability of cheaper products and lack of awareness among the population of underdeveloped areas are posing as a threat to the growth of the global clear aligners market.
Competitive Dashboard:
Globally, a large number of companies are working in the development and production of clear aligners. These major companies have adopted extensive research, in order to offer better and cost-effective products. The American and European regions are a hub for major companies, generating maximum market share which has turned these regions into a well-established market. These companies have expanded their operating units in various other regions as well. Moreover, there are various other small and medium scale players that generate revenue from the local market.
Some key players operating in this market are
  • Align Technology, Inc.,
  • Institut Straumann AG,
  • Danaher Corporation,
  • Dentsply Sirona,
  • Clarus,
  • 3M, among others.
Segmentation:
The global clear aligners market has been segmented into product type, age, distribution channel, and region.
Based on product type, the global market has been segmented into hard, medium, and soft.
Based on age, the global market has been divided into teenager and adult. The teenager segment is likely to hold the maximum share in the global market with a value of 1427.98 million in 2018.
Based on distribution channel, the global market has been divided into direct sales and distributor.
Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/report/covid-19-impact-clear-aligners-market
Detailed Regional Analysis:
The global clear aligners market, based on region, is segmented into– the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is expected to command the largest market share due to aesthetic dentistry and other vast specialized services present in countries of North America. Additionally, the rising health expenditure per person and increasing demand for advanced technologies are driving the growth of the clear aligners market in these countries. Additionally, the presence of a large number of noticeable players in this region is the major driving factor of the market in the Americas.
Europe accounts for the second-largest market, majorly due to the soaring demand for dental procedures. Additionally, the increasing incidences of oral problems, vast application of technologically advanced techniques, and the growing importance of treatment, planning, and diagnosis in implant dentistry in European countries are driving the clear aligners market in Europe.
Asia-Pacific with lots of opportunities and continuously growing economies is expected to be the fastest-growing region. Furthermore, recent developments in healthcare and improving economies and disposable income per individual are fueling market growth.
The Middle East & Africa is expected to grow significantly during the forecast period due to the increasing cases of dental abnormalities and the demand for better teeth-related treatments in the region.
Browse Clear Aligners Market by Product Type, Age, Distribution Channel and Region @ https://www.marketresearchfuture.com/reports/clear-aligners-market-6974

Posted by at No comments:

Liquid Biopsy Market Forecasts By Industry Drivers, Regions Till 2023

Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart.
Segmentation:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Major Players 
  • Guardant Health, Inc.,
  • Trovagene, Inc.,
  • RainDance Technologies, Inc.,
  • Agena Bioscience Inc. Inc.,
  • Admera Health,
  • Biocept, Inc.,
  • Circulogene Theranostics,
  • Inivata Ltd.,
  • SAGA Diagnostics AB,
  • Exosome Diagnostics and others.
Drivers
The market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Key findings
  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period
Posted by at No comments:

Cranial Fixation and Stabilization Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

This cranial fixation and stabilization devices market size can be attributed to the growing healthcare market and the ever-expanding technology market. Advances in these fields have created an environment that is conducive to the development of specialized surgical procedures for traditionally high-risk surgeries.
According to the UN, globally, one in six individuals suffers from a neurological disorder. There are several invasive surgeries that being developed to treat such conditions, requiring cranial fixation and stabilization equipment.
The Global Cranial Fixation and Stabilization Market is expected to reach USD 2.29 Billion by 2025, registering a CAGR of 8.90%.
SEGMENTATION
By Category
Cranial stabilization equipment is used to secure the head during surgery, while cranial fixation implements are tools required to maintain the structural stability of the head and neck.
  • Cranial Fixation Systems: Cranial fixation covers a wide array of tools and implements such as meshes, flap tube clamps, plates, and screws to be used during surgery. They are used predominantly for affixing bones, securing skin, and enhancing cranial integrity post-surgeries such as craniotomies.
  • Cranial Stabilization Systems: Cranial surgeries are usually very delicate and complex, necessitating the use of equipment to immobilize the head. This is accomplished by the use of cranial stabilization equipment such as skull clamps and horseshoe headrests.
By Product
  • Meshes: The leading market segment as 48% of all cranial injuries are maxillofacial. Over 52% of road accident-related injuries are mandibular fractures that require meshes.
  • Skull Clamps: Ideal for prolonged surgeries that require patient immobilization for long periods with limited soft tissue damage. Used to hold the head firmly in place during surgery.
  • Flap Tube Clamps: Used to attach cranial bones to the cranium during delicate surgeries when only a singular motion can be performed upon the afflicted area.
  • Horseshoe Headrests: Used in cases where head movement is not to be completely restrained and soft tissue damage needs to be minimized.
  • Plates: Used to seal gaping cranial wounds.
  • Screws: Facilitate the attachment of cranial bones.
  • Accessories: Include patient positioning systems and support systems.
By Type
  • Resorbable: Materials that are eventually broken down by the body. The growth of the segment is limited by the high costs of the equipment.
  • Non-Resorbable: These are biocompatible and offer unparalleled rigidity and stability to the cranium. Used extensively in developing countries due to their low costs.
By End User
  • Hospitals: The segment commands the largest share of the global cranial fixation and stabilization market as most cranial surgeries are performed in hospitals. Cranial surgeries require the latest equipment and amenities, along with a high level of expertise, which are offered by hospitals.
  • Ambulatory Surgical Centers: As emergency and temporary patient-stabilization surgeries are performed at these centers, the segment accounts for a small market share, which is somewhat offset by the higher revenue per surgery generated.
  • Others: This segment includes on-site trauma and emergency surgeries. This is a niche segment with growth potential due to the establishment of trauma centers at industrial complexes.
 By Region
  • Americas: Largest regional market, with North America accounting for 55% of the global market share.
  • Asia-Pacific: Fastest growing regional market
  • Europe: Second-largest market
  • Middle East & Africa
Key Players
  • Johnson & Johnson (US)
  • Stryker (US)
  • Ostomed (UK)
  • KLS Martin Group (Germany)
  • Medtronic (US)
  • Integra LifeSciences Corporation (US)
  • Braun Melsungen AG (Germany)
  • Changzhou Huida (China)
  • DePuy Synthes (US)
  • Evonos (Germany)
  • Jeil Medical (South Korea)
  • Medicon (Germany)
  • Micromar (Brazil)
  • NEOS Surgery (Spain)
  • Pro Med Instruments (Germany)
  • Zimmer Biomet (US)
Posted by at No comments:
Subscribe to: Posts (Atom)